In addition, the mammalian target of rapamycin (mTOR) pathway alterations which reactivate the HER2 signaling axis and which induce the hyper-activation of the HER kinase signaling are important drivers of neratinib resistance in HER2 mutant cancers(Collins et al. 2019; Sudhan et al. 2020a, b). The gene discussed is ERBB2; the disease is cancer.